Navigation Links
Ovarian cancer study offers vital clues for new therapies
Date:4/21/2010

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

Researchers have found that patients with hereditary ovarian cancer whose tumours are caused by faulty genes are more likely to experience secondary tumours in their liver and spleen. This is despite the fact that their overall prognosis is better than other patients.

In non-hereditary cancer, ovarian tumours tend to remain within the lining of the abdomen and pelvis.

A University of Edinburgh study suggests that ovarian cancer patients whose tumours spread to the solid organs such as the liver and lungs should be tested for the faulty genes BRCA1 and BRCA2 to ensure they are given the most appropriate treatment.

Researchers say this would improve the detection of these faulty genes as current criteria for genetic testing may miss as many as two-thirds of ovarian cancer patients carrying faulty BRCA genes.

Patients with hereditary tumours, which account for 10 per cent of ovarian cancers, may also be suitable for trials of a new drug called olaparib, which has fewer side-effects than normal cancer treatments.

Improving the identification of BRCA mutations would help relatives of ovarian cancer patients, who may themselves be at increased risk of developing hereditary cancer.

The research is published in the Journal of Clinical Oncology.

Dr Charlie Gourley, who led the research at the University of Edinburgh, said: "We are beginning to understand the importance of tailoring cancer treatments according to the specifics of each patient's tumour. These findings demonstrate that tumours which arise because of defects in the BRCA1 or BRCA2 genes behave differently to other ovarian cancers. This information should also help us to identify the patients carrying these genetic mutations, give them the most effective treatment for their cancer and offer their relatives genetic counselling."


'/>"/>

Contact: Anna Borthwick
anna.borthwick@ed.ac.uk
44-131-651-4400
University of Edinburgh
Source:Eurekalert

Related medicine news :

1. Only women with Western Swedish breast cancer gene run higher risk of ovarian cancer
2. Pre-Diagnosis Diet Linked to Ovarian Cancer Survival
3. Study finds delay in referrals for older women with ovarian cancer
4. Foster Friess commits up to $50,000 to help TGen fight ovarian cancer
5. How to make the best decisions when at high risk for breast or ovarian cancer
6. Symptoms have little value for early detection of ovarian cancer
7. Symptoms Alone Dont Spot Ovarian Cancer Early
8. Ultrasound plus proteomic blood analyses may help physicians diagnose early-stage ovarian cancer
9. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
10. Research suggests link between infertility, low egg reserve, and breast/ovarian cancer gene (BRCA1)
11. Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , ... September 25, 2017 , ... Bobbie Horowitz was ... Osteoarthritis and multiple health issues. As a cabaret and theater producer, Horowitz would manage ... main source of transportation in New York City, so she had to take a ...
(Date:9/25/2017)... ... September 25, 2017 , ... Physician Partners of America ... at 5304 Main Street as an interventional pain management specialist. , Dr. Gorman ... He joins PPOA from private practice In Brooksville, Fla. His orthopedic background puts him ...
(Date:9/25/2017)... Charles, LA (PRWEB) , ... September 25, 2017 , ... ... in Lake Charles, LA. “I could not imagine doing anything else,” said Dr. Hebert. ... me each and every day. The interactions with my patients is what I look ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a poignant ... “The Majestic Unicorn” is the creation of published author, Dayna Chantel, an artist and ... far and wide to march aboard the cypress ark-vessel. Male and female, no matter ...
(Date:9/25/2017)... VA (PRWEB) , ... September 25, 2017 , ... ... and Response Preconference Workshop, **Presented by FDAnews**, Nov. 1-3, 2017 – Bethesda, MD, ... drugmaker passed with flying colors. And then, on the tenth inspection it failed. ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
(Date:9/9/2017)... INDIANAPOLIS , Sept. 9, 2017  Eli Lilly ... key primary and secondary endpoint data for lasmiditan, an ... migraine, which demonstrated statistically significant improvements compared to placebo ... be highlighted today at the 18th Congress of the ... . "The data presented today demonstrate lasmiditan,s ...
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
Breaking Medicine Technology: